A Mathematical Modeling Approach for Targeted Radionuclide and Chimeric Antigen Receptor T Cell Combination Therapy

被引:12
作者
Adhikarla, Vikram [1 ]
Awuah, Dennis [2 ]
Brummer, Alexander B. [1 ]
Caserta, Enrico [3 ]
Krishnan, Amrita [2 ]
Pichiorri, Flavia [3 ]
Minnix, Megan [4 ]
Shively, John E. [4 ]
Wong, Jeffrey Y. C. [5 ]
Wang, Xiuli [2 ]
Rockne, Russell C. [1 ]
机构
[1] City Hope Natl Med Ctr, Div Math Oncol, Dept Computat & Quantitat Med, Beckman Res Inst,Natl Med Ctr, Duarte, CA 91010 USA
[2] City Hope Natl Med Ctr, Dept Hematol & Hematopoiet Cell Transplantat, Beckman Res Inst, Natl Med Ctr, Duarte, CA 91010 USA
[3] City Hope Natl Med Ctr, Dept Hematol Malignancies Translat Sci, Beckman Res Inst, Natl Med Ctr, Duarte, CA 91010 USA
[4] City Hope Natl Med Ctr, Dept Mol Imaging & Therapy, Natl Med Ctr, Duarte, CA 91010 USA
[5] City Hope Natl Med Ctr, Dept Radiat Oncol, Natl Med Ctr, Duarte, CA 91010 USA
基金
美国国家卫生研究院;
关键词
CAR-T; targeted radionuclide therapy; TRT; mathematical model; multiple myeloma; immunotherapy; daratumumab; CS1; combination therapy; alpha particle therapy; actinium-225; IMMUNOTHERAPY;
D O I
10.3390/cancers13205171
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Targeted radionuclide therapy (TRT) has recently seen a surge in popularity with the use of radionuclides conjugated to small molecules and antibodies. Similarly, immunotherapy also has shown promising results, an example being chimeric antigen receptor T cell (CAR-T) therapy in hematologic malignancies. Moreover, TRT and CAR-T therapies possess unique features that require special consideration when determining how to dose as well as the timing and sequence of combination treatments including the distribution of the TRT dose in the body, the decay rate of the radionuclide, and the proliferation and persistence of the CAR-T cells. These characteristics complicate the additive or synergistic effects of combination therapies and warrant a mathematical treatment that includes these dynamics in relation to the proliferation and clearance rates of the target tumor cells. Here, we combine two previously published mathematical models to explore the effects of dose, timing, and sequencing of TRT and CAR-T cell-based therapies in a multiple myeloma setting. We find that, for a fixed TRT and CAR-T cell dose, the tumor proliferation rate is the most important parameter in determining the best timing of TRT and CAR-T therapies.
引用
收藏
页数:14
相关论文
共 26 条
[1]   T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma [J].
Ali, Syed Abbas ;
Shi, Victoria ;
Maric, Irina ;
Wang, Michael ;
Stroncek, David F. ;
Rose, Jeremy J. ;
Brudno, Jennifer N. ;
Stetler-Stevenson, Maryalice ;
Feldman, Steven A. ;
Hansen, Brenna G. ;
Fellowes, Vicki S. ;
Hakim, Frances T. ;
Gress, Ronald E. ;
Kochenderfer, James N. .
BLOOD, 2016, 128 (13) :1688-1700
[2]   Dosimetric Analysis of the Short-Ranged Particle Emitter 161Tb for Radionuclide Therapy of Metastatic Prostate Cancer [J].
Bernhardt, Peter ;
Svensson, Johanna ;
Hemmingsson, Jens ;
van der Meulen, Nicholas P. ;
Zeevaart, Jan Rijn ;
Konijnenberg, Mark W. ;
Muller, Cristina ;
Kindblom, Jon .
CANCERS, 2021, 13 (09)
[3]   Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach? [J].
Bernstein, Michael B. ;
Krishnan, Sunil ;
Hodge, James W. ;
Chang, Joe Y. .
NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (08) :516-524
[4]   The linear-quadratic model and most other common radiobiological models result in similar predictions of time-dose relationships [J].
Brenner, DJ ;
Hlatky, LR ;
Hahnfeldt, PJ ;
Huang, Y ;
Sachs, RK .
RADIATION RESEARCH, 1998, 150 (01) :83-91
[5]   T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma [J].
Brudno, Jennifer N. ;
Maric, Irina ;
Hartman, Steven D. ;
Rose, Jeremy J. ;
Wang, Michael ;
Lam, Norris ;
Stetler-Stevenson, Maryalice ;
Salem, Dalia ;
Yuan, Constance ;
Pavletic, Steven ;
Kanakry, Jennifer A. ;
Ali, Syed Abbas ;
Mikkilineni, Lekha ;
Feldman, Steven A. ;
Stroncek, David F. ;
Hansen, Brenna G. ;
Lawrence, Judith ;
Patel, Rashmika ;
Hakim, Frances ;
Gress, Ronald E. ;
Kochenderfer, James N. .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (22) :2267-+
[6]   Copper 64-labeled daratumumab as a PET/CT imaging tracer for multiple myeloma [J].
Caserta, Enrico ;
Chea, Junie ;
Minnix, Megan ;
Viola, Domenico ;
Vonderfecht, Steven ;
Yazaki, Paul ;
Crow, Desiree ;
Khalife, Jihane ;
Sanchez, James F. ;
Palmer, Joycelynne M. ;
Hui, Susanta ;
Carlesso, Nadia ;
Keats, Jonathan ;
Kim, Young ;
Buettner, Ralf ;
Marcucci, Guido ;
Rosen, Steven ;
Shively, John ;
Colcher, David ;
Krishnan, Amrita ;
Pichiorri, Flavia .
BLOOD, 2018, 131 (07) :741-745
[7]   Chimeric Antigen Receptor T Cell Therapies: A Review of Cellular Kinetic-Pharmacodynamic Modeling Approaches [J].
Chaudhury, Anwesha ;
Zhu, Xu ;
Chu, Lulu ;
Goliaei, Ardeshir ;
June, Carl H. ;
Kearns, Jeffrey D. ;
Stein, Andrew M. .
JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 60 :S147-S159
[8]   Bridging Radiation Is an Effective Strategy to Control Lymphoma in Preparation for CAR-T: A City of Hope Experience [J].
Dandapani, Savita ;
Shouse, Geoffrey ;
Yeh, Jekwon ;
Thai Cao ;
Wong, Jeffrey ;
Budde, Lihua E. .
BLOOD, 2020, 136
[9]   A review of cancer immunotherapy: from the past, to the present, to the future [J].
Esfahani, K. ;
Roudaia, L. ;
Buhlaiga, N. ;
Del Rincon, S., V ;
Papneja, N. ;
Miller, W. H., Jr. .
CURRENT ONCOLOGY, 2020, 27 :S87-S97
[10]   Future of Radiation and Immunotherapy [J].
Formenti, Silvia C. ;
Demaria, Sandra .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (01) :3-5